Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
J. Nicholas Bodor(Fox Chase Cancer Center), Joseph Treat(Fox Chase Cancer Center), Vinicius Ernani(Emory University), C. Patrick, Ari M. Vanderwalde(West Cancer Center), Joanne Xiu(Caris Life Sciences (United States)), Supreet Kaur(The University of Texas at San Antonio Health Science Center), Sai Hong I Ou, Margie L. Clapper, Hossein Borghaei(Fox Chase Cancer Center), Hirva Mamdani(Wayne State University)
Cited by 1
Related Papers
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
|Journal of Clinical Oncology|2000|286
Long-Term Implantation of Preadipocyte-Seeded PLGA Scaffolds
|Tissue Engineering|2002|210